Futura Medical
Guildford, United Kingdom

Futura Medical is a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and a lead programme, MED3000, in development for erectile dysfunction.


Investment Perspective

During 2022 Futura Medical successfully delivered on several key MED3000 related events, including the highly positive FM71 longer-term clinical data, which are needed to enter the US market and importantly reinforced MED3000’s differentiated and rapid onset of action. In addition, a number of commercial deals were executed, notably the European and UK deal with Cooper Consumer Health. The next steps are EU launches (due to start during H123), FDA marketing clearance (potentially by end Q123), and securing a US partner. These should be the final elements in converting MED3000 into a revenue generating OTC product for ED, transforming Futura Medical’s prospects. Pending visibility on both US and European launches, our updated model conservatively does not include any near-term MED3000 related revenues. Our Futura Medical valuation is now £270m, equivalent to 94p per share.

Market information

SymbolPrimary exchanges


On the cusp of MED3000 commercialisation
Update | 10 Nov 2022
Interims highlight positive first signs in key markets
Lighthouse | 13 Sep 2022
FM71 achieves all primary and secondary endpoints
Lighthouse | 31 Aug 2022

Recent News

Application to the US FDA for MED3000
03 Oct 2022
Interim H122 results
13 Sep 2022
Highly positive FM71 Phase III data
31 Aug 2022
MED3000 Collaboration in EEA, UK & Switzerland
23 May 2022